HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Apple Series 6 Watch Pumps Mobile Access To Blood Oxygen Saturation Measurement

Executive Summary

The company is sponsoring research on how the blood oxygen sensor feature on its Apple Watch 6 could be applied to specific health problems.

You may also be interested in...



Fitbit Has OTC Electrocardiogram App To Rival Apple, Samsung With Clearance In US, EU

Fitbit will launch its new Fitbit Sense smartwatch with ECG app in Europe, US, Hong Kong and India in October. 

Fitbit Receives FDA Clearance, CE Mark For ECG App To Rival Apple

Fitbit will launch its new Fitbit Sense smartwatch with ECG app in Europe, US, Hong Kong and India in October. 

LifeSignals Plans To Market Biosensor Patch To Help Consumer Identify COVID-19 Symptoms

LifeSignals plans to soon launch a biosensor patch to consumers to help them monitor for potential symptoms of COVID-19. 

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150477

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel